Sara A. Hurvitz, MD, on Outcomes for Different Racial Groups Treated With Talazoparib for Breast Cancer

Posted: Tuesday, April 21, 2020

Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses the self-reported outcomes of women from different racial groups with HER2-negative locally advanced or metastatic breast cancer and a germline BRCA1/2 mutation who were treated with the PARP inhibitor talazoparib vs chemotherapy in the EMBRACA trial.